Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC

被引：0
|
作者：
Janne, P. [1 ]
Yu, H. [2 ]
Johnson, M. [3 ]
Steuer, C. [4 ]
Vigliotti, M. [5 ]
Shipitofsky, N. [5 ]
Guevara, F. M. [5 ]
Chen, S. [5 ]
Yu, C. [5 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
EGFR mutation; Drug resistance; HER3;
D O I：
10.1016/j.jtho.2018.08.1438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.13-43
引用
收藏
页码：S815 / S816
页数：2
相关论文
共 50 条
  • [1] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Vigliotti, M.
    Shipitofsky, N.
    Singh, J.
    Guevara, F.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2290 - S2290
  • [2] Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Janne, Pasi A.
    Yu, Helena Alexandra
    Johnson, Melissa Lynne
    Vigliotti, Michele
    Shipitofsky, Nicole
    Guevara, Ferdinand Morales
    Chen, Shuquan
    Yu, Channing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Sakai, Kazuko
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Goto, Hiroki
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2021, 32 : S296 - S296
  • [4] Preliminary Phase 1 Results of U3-1402-A Novel HER3-Targeted Antibody-Drug Conjugate-in EGFR TKI-Resistant, EGFR-Mutant NSCLC
    Yu, H.
    Johnson, M.
    Steuer, C.
    Vigliotti, M.
    Chen, S.
    Kamai, Y.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S336 - S337
  • [5] EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402
    Haikala, Heidi M.
    Kohler, Jens
    Lopez, Timothy
    Eser, Pinar
    Xu, Man
    Yu, Channing
    Shiose, Yoshinobu
    Qiu, Yang
    Gokhale, Prafulla
    Janne, Pasi A.
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
    Yu, H.
    Baik, C.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W.
    Yang, J. C.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S107 - S107
  • [7] Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.
    Janne, Pasi A.
    Yu, Helena Alexandra
    Johnson, Melissa Lynne
    Steuer, Conor Ernst
    Vigliotti, Michele
    Iacobucci, Corinne
    Chen, Shuquan
    Yu, Channing
    Sellami, Dalila B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
    Hayashi, Hidetoshi
    Yu, Helena A.
    Baik, Christina
    Gold, Kathryn
    Johnson, Melissa L.
    Koczywas, Marianna
    Murakami, Haruyasu
    Nishio, Makoto
    Steuer, Conor
    Su, Wu-Chou
    Yang, James C. H.
    Karam, Samer
    Qui, Zhenhao
    Qiu, Yang
    Chen, Shuquan
    Yu, Channing
    Janne, Pasi A.
    ANNALS OF ONCOLOGY, 2021, 32 : S318 - S318
  • [9] Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer
    Kogawa, Takahiro
    Yonemori, Kan
    Naito, Yoichi
    Noguchi, Emi
    Shimizu, Chikako
    Tamura, Kenji
    Hosono, Ako
    Matsubara, Nobuaki
    Sugihara, Masahiro
    Ogawa, Hayao
    Majima, Shuji
    Yu, Channing
    Ueno, Suguru
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
    Yu, H. A.
    Baik, C. S.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W-C.
    Yang, J.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1189 - S1190
12345